Register
Login:
Share:
Email Facebook Twitter

Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 47.50Bid: 46.00Ask: 49.00Change: 2.00 (+4.40%)Riser - Immupharma
Spread: 3.00Spread as %: 6.52%Open: 48.50High: 49.50Low: 47.50Yesterday’s Close: 45.50
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
47.50

Share Price SpacerBid
46.00

Share Price SpacerAsk
49.00

Share Price SpacerChange
4.40%2.00

Share Price SpacerVolume
208,798

Share Price SpacerOpen
48.50

Share Price SpacerHigh
49.50

Share Price SpacerLow
47.50

Share Price SpacerClose
45.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 82.28m £39.08m 5,000

52 Week High 71.00 52 Week High Date 18-OCT-2013
52 Week Low 41.50 52 Week Low Date 9-JUN-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
30 67,222 115,420 -10.509 -4.52 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

30-Sep-14
17:07:45
47.50
18,500
 
46.00
49.00
8,788
Trade Type:
Ordinary

30-Sep-14
15:28:05
47.375
817
Sell* 
46.00
49.00
387.05
Trade Type:
Ordinary

30-Sep-14
14:34:20
47.50
3,142
 
46.00
49.00
1,492
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
23-Jan-12Buy
Trade Notifier Information for Immupharma
Franco Di Muzio held the position of Non-Executive Director at Immupharma at the time of this trade.
 Franco Di Muzio
81GBX60,9500
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 17:05
leas
RE: Today's news
47.50
No Opinion

Good post Dibs, good overview. The rewards are there to see if p3 is a success. Today really confirms what we already know. Knowing the partner is the key here which we should know very soon. I suspect the finer details in relation to funding and future royalties are the sticking points. The way things are on the AIM atm makes this a good day in relation to the sp. Majority of other companies would see the sp in decline as uncertainty still remains on who that partner is and the funding so overall I am more than happy. I'm sure by the end of 2015 I will be even happier. Lots of scenarios to consider here but if you believe p3 will be a success then the current MC makes this a 'no brainer'
Today 16:18
Dibs61
Today's news
47.50
Buy

Market digesting. Modest reaction due to lack of concrete agreement and no detail. Don't know who partner is? Funding requirements, who pays what? Will Darwin be used (I hope not). Once we have confirmation and details it might be possible to put a valuation in place. I was considering topping up this morning but glad I held back for now. Given that something like 80% of phase III's succeed this is a darned good risk to reward ratio now. £5m of the current £37m mc is cash meaning Lupuzor and all the other assets valued at £32m. That will look like the bargain of the year if phase 3 gets through. This has got to be worth a punt now in every AIM investors portfolio surely?
Today 15:36
wantonhearts
New Chapter
47.50
No Opinion

I think Turnashilling will henceforth be known as Goneaquiet.
Today 15:22
wantonhearts
Timescale Confirmed - "Few wee..
47.50
Strong Buy

Updated comment from DD just released via Proactive Investor article: “We should have something more in the next few weeks,” chief executive Dimitri Dimitriou told Proactive Investors. “When we have more details, we will discuss them. Until then we can’t speculate.” WH
Today 15:14
khameeleon
dots
47.50
No Opinion

Good to see the unheard of red dot flashing on the IMM screen.....feel like I should take a screen shot!
Today 14:59
panda1
Great News
47.50
No Opinion

I am very happy that the company is finally entering into a phase III trial for Lupuzor. The drug, which we know is a potential blockbuster and very high margin, could be worth may multiples of the company's current market cap. Buried in today's release is some very important data: "Commercial Opportunity Current drugs either have serious side effects or have limited effectiveness GSK's Benlysta's approval paves the way for Lupuzor™ (first Lupus drug approved in over 50 years) There are an estimated 1.5 million patients in US, Europe and Japan The target price per patient is estimated to be around $10,000 -$20,000 per year". So sales could be huge. Boomorbust summed the opportunity up nicely: "Don't think many PI's appreciate just what an achievement taking a drug into phase III is. According to the FDA the probability of a new drug reaching phase III studies is only 8% so if you look at every bio on AIM and every product they have in development only 8% of them will get this far. More importantly though once there the FDA estimate that the probability of approval and reaching the market is 90%." The risk to reward ratio at the current low share price is very enticing. There should be plenty of newsflow now the starting gun has been fired to drive the sp significantly higher. The cancer drug also sounds promising which seems to be currently valued by the market at Zero.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.